Joachim Bischoff

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Kimberly Blackwell, Harold J. Burstein, Anna Maria Storniolo et al. · Journal of Clinical Oncology · 2010 · 960 citations · Full text

Medicine, Oncology, Pharmacology +17

From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression

Oleg Schmidt‐Kittler, Thomas Ragg, Angela Daskalakis et al. · Proceedings of the National Academy of Sciences · 2003 · 624 citations · Full text

Medicine, Genetics, Oncology +17

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

Kimberly Blackwell, Harold J. Burstein, Anna Maria Storniolo et al. · Journal of Clinical Oncology · 2012 · 544 citations

Medicine, Oncology, Pharmacology +17

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

Michael Untch, Sibylle Loibl, Joachim Bischoff et al. · The Lancet Oncology · 2012 · 454 citations

Medicine, Oncology, Pharmacology +17